x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

29:18

88. On the Road with Dr. Geoffrey Shapiro

Oncology for the Inquisitive Mind ·

2024/02/10

We return to the Dana Farber Cancer Institute this week as part of our "On the Road" series and interview the multitalented Dr. Geoffrey Shapiro. Dr Shapiro completed his medical training at Cornell University and received his PhD in 1987. His passions lie in early-phase drug development and clinical trials, with a specific flair for cell cycle and DNA repair inhibitor therapeutics. Dr. Shapiro provides an insightful take on drug development, current opportunities, challenges, the world of CDK

en

32:20

87. On the Road with Dr. Eric Winer

Oncology for the Inquisitive Mind ·

2024/02/03

Today, we interview Dr. Eric Winer, our second guest in our mini-series "On the Road". Dr Winer is no ordinary Oncologist; he is a prolific clinician and researcher, despite being born with haemophilia and living with the consequences of early treatment for this, including HIV. In this episode, OFTIM explores his formative years, challenges and triumphs as he provides unique insights as both a patient and a clinician. This episode was recorded live in front of a captive audience in Sydney,

en

45:02

86. On the Road with Dr. Erica Mayer

Oncology for the Inquisitive Mind ·

2024/01/27

Today, we interview Dr. Erica Mayer as our first guest in the "On the Road" mini-series. Dr. Mayer is a renowned breast cancer oncologist at the Dana Farber Cancer Institute. Each week for the next seven weeks, Michael and Josh will introduce a new guest to share their wealth of experience, expertise and wisdom, covering all the essential topics from career development, mentorship and necessary trials and challenges in the oncology world.Dr. Mayer graduated from Harvard Medical School and completed

en

29:38

85. Spotlight: Year in Retrospect: 2023

Oncology for the Inquisitive Mind ·

2024/01/20

Oncology for the Inquisitive Mind is back, and we have a blockbuster year ahead! Before we get there, we have our year in review 2023. Michael and Josh have poured over the treasure trove of pivotal trials from 2023 to bring you the best studies (in our opinion) from the last 365 days! We used various complex metrics involving no science or maths at all.Just when you thought you were free from oncology learning, we drag you back in, much like Al Pacino's character from The Godfather is famously

en

28:58

84. World Conference on Lung Cancer (part 2)

Oncology for the Inquisitive Mind ·

2023/12/30

2023 has been a year of highs and lows, a calendar of peaks and troughs, an epoch of mountains and valleys (all right Michael, put the thesaurus away...). From standing ovations for enfortumab vedotin and vorasidenib, to the ongoing black hole that is effective treatments for pancreatic and hepatocellular carcinomas. However, through it all the brightest minds in the field have continued to stoke the fires of hope with the development of novel antibody-drug conjugates, immunotherapies and clever

en

36:16

83. World Conference on Lung Cancer (part 1)

Oncology for the Inquisitive Mind ·

2023/12/23

ASCO and ESMO are done, and soon, 2023 itself will be in the rearview mirror. And yet, there are still conferences happening around the world; yes, we know the World Conference on Lung Cancer occurred before ESMO, but there is such a thing as too much of a good thing. Join Michael and Josh on their latest virtual journey abroad, this time to the equatorial island of Singapore, as they report on two of their favourite studies from WCLC 2023. For those who celebrate, have a Merry Christmas and a happy

en

15:35

Oncosnacks 12: Enfortumab Vedotin skin toxicity...

Oncology for the Inquisitive Mind ·

2023/12/19

On this episode, their final of 2023, Michael and Josh return to the world of recent fan favourite, enfortumab vedotin (EV). Not content to sing its praises from every rooftop, our intrepid hosts take the necessary step of examining the common and sometimes severe manifestations of dermatological toxicity deriving from EV. With the assistance of a recently published guideline, they examine the presentation, assessment and management of skin toxicity.From all of us at OftiM, we would like to thank

en

35:58

82. Metastatic triple negative breast cancer (TNBC)

Oncology for the Inquisitive Mind ·

2023/12/16

Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space

en

22:24

Fireside Chats 2. Time Toxicity in Early Phase Trials

Oncology for the Inquisitive Mind ·

2023/12/12

For patients with advanced cancer, early-phase trials may represent the last best hope of significant anticancer response. For clinicians, every early phase trial holds virtually unlimited promise and hope of becoming the next immunotherapy or hot antibody-drug conjugate. However, early-phase trials also come with significant uncertainty of efficacy, toxicity and even dosing.A recent Limbic article (link below) reported on an article published in ESMO Open that investigated the burden of "time

en

29:55

81. San Antonio Breast Cancer Symposium Update

Oncology for the Inquisitive Mind ·

2023/12/09

San Antonio Breast Cancer Symposium is here, and this year, OFTIM (Oncology for the Inquisitive Mind) is bringing you the latest and greatest in all things breast cancer. With over 10000 attendees, the research and vibrant discussions did not disappoint, with updates, controversies and complexities. Taking centre stage were PIK3CA mutation treatments, updates on CDK4/6 inhibitors and the age-old question - does exercise improve outcomes for our patients?Studies discussed in today's episode

en

30:54

80. ESMO 2023 - Plenary Session

Oncology for the Inquisitive Mind ·

2023/11/07

Today, OFTIM celebrates its 80th episode and presents its ESMO23 plenary session, including two practice-changing, paradigm-shifting trials. The first investigates the EGFR mutation Non-Small Cell Lung Cancer world with new drugs (amivantamab and lazertinib) to treat patients hose who progressed on osimertinib. The second trial is the EV-302/KEYNOTE-A39, which explores whether enfortumab vedotin (ADC) and pembrolizumab (immunotherapy) can best-platinum-based chemotherapy. No prior trial has ever

en

23:21

79. ESMO 2023 - Gynaecological Oncology

Oncology for the Inquisitive Mind ·

2023/11/06

As Oncology for the Inquisitive Mind's coverage of ESMO 2023 winds down, we bring some of the best presentations covering gynaecological cancer. An area of oncology that in many cases remains mired in the pre-immunotherapy and pre-targeted therapy ages, ESMO brought some much-needed positive trials in the areas of cervical cancer, as well as an interesting (albeit negative) study of the PARP-inhibitor olaparib that highlights some of the more practical challenges of running an international phase 3

en

23:12

78. ESMO 2023 - Skin Cancer and Melanoma

Oncology for the Inquisitive Mind ·

2023/11/05

Since the early development of immunotherapy, metastatic melanoma has been the golden child of medical oncology. In recent years, similar outcomes have been seen with immunotherapy in non-melanomatous skin cancers. Cemiplimab is now a standard of care for patients with locally advanced, unresectable or metastatic cSCC, and is particularly effective in patients with cancer driven by UV-induced DNA damage. However, oncologists and researchers are always looking for new and better ways to use

en

32:26

77. ESMO 2023 - Non Small Cell Lung Cancer

Oncology for the Inquisitive Mind ·

2023/11/02

Non-small cell lung cancer continues to show massive promise with new trials, better designs and exciting utilisation of existing therapies. Michael and Josh explore immunotherapy in a "sandwich setting" where nivolumab is given before and after surgery. Datopotamab deruxtecan, the new kid on the block, takes on the second-line champion docetaxel. Who will win, and will docetaxel finally be dethroned? And potentially the most promising and exciting addition to this lineup is AZD7789, a new

en

23:11

76. ESMO 2023 - Colorectal Cancer (Part 2)

Oncology for the Inquisitive Mind ·

2023/11/01

Metastatic colorectal cancer has an average overall survival of three years. With limited treatment options as standard of care or effective targetable mutations, ESMO23 shined, providing answers to unanswered questions and a potentially brighter future for this cancer. Concerningly, we are seeing higher rates of colorectal cancer in lower and middle-income countries and those under the age of 50. We explore sotorasib in KRASG12C mutated cancers with panitumumab, the use of aspirin to reduce the

en

22:44

75. ESMO 2023 - Colorectal Cancer (Part 1)

Oncology for the Inquisitive Mind ·

2023/10/31

Colorectal cancer remains the bread and butter of many an oncologist, but its commonality belies its complexity. In early and advanced disease alike, there remain many permutations, considerations and controversies regarding optimal treatment. What is the best way to treat potentially-resectable colorectal cancer with liver metastases (CRLM)? Is there a way to increase the responsiveness to immunotherapy in patients with proficient mismatch repair (pMMR)? And are we moving to a brighter future where

en

24:48

74. ESMO 2023 - Upper GI and Hepatobiliary Cancer

Oncology for the Inquisitive Mind ·

2023/10/30

Next up on the ESMO 2023 rollercoaster is an episode that is likely to be the shortest in our series: upper gastrointestinal and hepatobiliary oncology. As always, this remains a very challenging subarea of medical oncology, both in the clinical and trial spheres. However, our esteemed colleagues at ESMO remain undaunted by this challenge, and thus several studies of interest bear discussing. Will any of these studies lead to massive upheavals for clinicians and patients alike? For that answer,

en

27:13

73. ESMO 2023 - Genitourinary Cancers - Prostate and...

Oncology for the Inquisitive Mind ·

2023/10/30

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make

en

31:40

72. ESMO 2023 - Early Breast Cancer (Part 2)

Oncology for the Inquisitive Mind ·

2023/10/27

Welcome back to Oncology for the Inquisitive Mind's ongoing coverage of ESMO 2023. In the spirit of a worldwide oncology conference, here we present results from three very exciting trials in the early breast phase. Will immunotherapy begin to carve out a niche in early, high-risk, ER-positive breast cancer? Can atezolizumab demonstrate a benefit in early TNBC, and expand its own territory? Is abemaciclib pulling away from its rivals in the treatment of high-risk, ER-positive breast cancer? Will

en

24:04

71. ESMO 2023 - Early Breast Cancer (Part 1)

Oncology for the Inquisitive Mind ·

2023/10/25

Every so often, an area of medical oncology has so many interesting presentations at a seminal conference that it becomes impossible to leave them out. At such times, Josh and Michael merely shrug their shoulders and say "why don't we do all of them." ESMO 2023 is one such instance. Despite their best efforts, our intrepid duo were unable to narrow down their presentation of early breast cancer highlights to one episode, so they are going to do two (for the price of one).Articles discussed in this

en

202 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown